Pieris Pharma (PIRS) Says It Presented Positive Data for Lead Drug Candidate PRS-343
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/16/2024
- Futures ease as bond yields stay elevated amid Middle East tensions
- UnitedHealth to take up to $1.6 billion hit from Change Healthcare hack this year
- Morgan Stanley's profit rises as investment banking recovers
- Johnson & Johnson (JNJ) posts mixed results, narrows full-year guidance
- Asian shares slide on Fed rate cut rethink; China GDP in focus
- Trump Media & Technology Group (DJT) Files S-1
- Tesla (TSLA) Senior VP Drew Baglino Is Said To Leave The Company - Bloomberg
- General Motors (GM) Said to be Moving Detroit HQ to Dan Gilbert's Hudson Tower - Bloomberg
- The Israeli Air Force Has Completed Its Preparation For An Imminent Attack Against Iran - Reuters
- Biohaven Pharma (BHVN) presents update on degrader platform and summary of progress to date in Phase 1 single ascending dose study for BHV-1300
- After-hours movers: Tesla, Gildan Activewear, Macatawa Bank, and more
- Midday movers: Goldman Sachs and Meta Platforms rise; Apple and Tesla fall
- Nike, Alpine Immune Sciences rise premarket; CarMax, Robinhood and Regeneron fall
- After-hours movers: Alpine Immune Sciences, Costco, and more
- Midday movers: Delta, Taiwan Semiconductor rise; Hexcel falls
Oppenheimer Reiterates Bullish View on Pieris Pharmaceuticals (PIRS) Following CRI Presentation
September 27, 2016 12:13 PM EDTOppenheimer analyst Michelle Gilson reiterated an Outperform rating and $10 price target on Pieris Pharmaceuticals (NASDAQ: PIRS) after the company presented a poster on its wholly-owned bispecific anticalin/mAb fusion protein PRS-343 (HER2xCD137), demonstrating in vivo efficacy compared to HER2 and CD137 (4-1BB) monocloanal... More
Roth Capital Affirms Pieris Pharma (PIRS) at 'Buy' Following Positive PRS-343 Data
September 27, 2016 10:48 AM EDTRoth Capital affirms Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS) at Buy with a price target of $6 after the company announced that it presented new preclinical data demonstrating in vivo efficacy of its lead 4-1BB (CD137)-based bispecific cancer immunotherapeutic drug candidate, PRS-343.
Analyst... More
